Telemedicine for children with sickle cell disease
Telemedicine for Pediatric Sickle Cell Patients in Medically Underserved Areas
NA · Indiana University · NCT05087303
This study is testing two different telemedicine approaches to see if they can help children with sickle cell disease get better care and support from home.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 16 Years and up |
| Sex | All |
| Sponsor | Indiana University (other) |
| Locations | 1 site (Indianapolis, Indiana) |
| Trial ID | NCT05087303 on ClinicalTrials.gov |
What this trial studies
This study aims to explore how two different telemedicine models can improve access to comprehensive care for children with sickle cell disease. The first aim is to adapt these telemedicine models based on caregiver feedback from previous work. The second aim focuses on testing the feasibility of these models in real clinical settings, while the third aim evaluates their effectiveness by measuring various outcomes, including patient satisfaction and clinical results. The study will involve caregivers and adolescents in interviews and surveys to gather insights on the care process.
Who should consider this trial
Good fit: Ideal candidates include caregivers of children aged 0 to 21 years with a diagnosis of sickle cell disease who are willing to use telemedicine for their care.
Not a fit: Patients receiving chronic transfusion therapy will not benefit from this study as the telemedicine models do not support their treatment needs.
Why it matters
Potential benefit: If successful, this study could enhance access to care and improve health outcomes for children with sickle cell disease.
How similar studies have performed: Other studies have shown promise in using telemedicine for chronic conditions, suggesting potential success for this approach in sickle cell disease.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Caregivers must be 18 years or older, who have children between 0 to 21 years old with a diagnosis of Sickle Cell Disease and receive care at the Riley Hospital for Children Comprehensive Sickle Cell Disease clinic. * Adolescent patients 16 years and older are also able to participate in interviews/surveys. * The family must be willing to receive their care using the telemedicine model available to them based on the location of their primary residence. * TeleSCD model participants must live within 1 hour of the pre-identified telemedicine sites, while VirtualSCD model participants must live within the city limits of the pre-identified area. Exclusion Criteria: * If a patient receives chronic transfusion therapy, they will not be eligible to participate, as our telemedicine models will not support this.
Where this trial is running
Indianapolis, Indiana
- Indiana University — Indianapolis, Indiana, United States (RECRUITING)
Study contacts
- Principal investigator: Seethal Jacob, MD — Indiana University
- Study coordinator: Seethal Jacob, MD
- Email: seejacob@iu.edu
- Phone: 317-278-9662
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Anemia, Sickle Cell